Date: 2015-10-05
Type of information: Nomination
Compound:
Company: Epigenomics (Germany - USA)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 5, 2015, MDxHealth announced that it has strengthened its Board of Directors with the appointment of Mr. Walter Narajowski, a medical diagnostics business leader with over 25 years of industry experience.
Mr. Narajowski brings significant experience to MDxHealth in the launch and successful global commercialization of molecular diagnostics from across the industry, from infectious diseases to food safety. He is currently Senior Vice President / General Manager of Roka Bioscience, a molecular diagnostic company developing tests and instrument systems for the food industry. Prior to Roka, Mr. Narajowski was Chief Executive Officer of Pathway Diagnostics, a biomarker development and testing company, which was subsequently sold to Quest Diagnostics. For the majority of his career, Mr. Narajowski was with Abbott Laboratories where he served in a number of key positions, including Vice President, General Manager of Critical Care Products, Vice President, General Manager of Abbott's infusion pump business, and General Manager of Physician Office Diagnostics, and Director of Research and Development in Abbott Diagnostics. Mr. Narajowski received his MS in bioengineering from the University of Utah, and his BS in electrical engineering from the Illinois Institute of Technology. The Company also announces that Mr. Mark Myslinski has stepped down from the Board after five years of dedicated service to MDxHealth.
As a result of the aforementioned changes, the MDxHealth Board now consists of:
Greenlands Consulting L.L.C., represented by Mr. Edward L. Erickson, Chairman of the Board of Directors and Independent Director
Dr. Jan Groen, Chief Executive Officer and Executive Director
Mrs. Ruth Devenyns, Independent Director
Lab Dx L.L.C., represented by Mr. Walter Narajowski, Independent Director
Gengest BVBA, represented by Mr. Rudi Mariën, Non-Executive Director
Valiance Advisors LLP, represented by Mr. Jan Pensaert, Non-Executive Director
Following the recent acquisition of NovioGendix, Prof. Dr. Jack Schalken will also serve as an independent advisor to the Company and the Board of Directors.
Financial terms:
Latest news:
